Multigene prognostic assay for lung cancer
US9476098B2 · kind B2 · utility
1Cited by
1References
35Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 29, 2012 |
| Grant date | Oct 25, 2016 |
| Priority date | — |
| Expiry date | Jul 22, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5-year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.